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Introduction: Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging
scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted
either prolactin or adrenocorticotropic hormone, and another 24% were non-secreting.
Case presentation: A 42-year-old Caucasian man lived for 30 years after the diagnosis of a pituitary tumor whose
clinical and biochemical features were those of acromegaly and hypogonadism. Radiotherapy, totaling 7300 rad, was
administered to the sella over two courses. Growth hormone levels normalized, but he developed both thyroid and
adrenal insufficiency, and replacement therapy was commenced. Fourteen years later, growth hormone levels again
became elevated, and bromocriptine was commenced but led to side effects that could not be tolerated. An
attempted surgical intervention failed, and octreotide and pergolide were used in succession. Twenty-seven years
after the diagnosis, a mass from an excisional biopsy of below the angle of the mandible proved to be metastatic
pituitary carcinoma. Immunohistochemical staining was positive for synaptophysin, growth hormone, and prolactin.
One year later, an octreotide scan showed uptake at the sella, neck, and spleen. Our patient declined further active
oncology treatment.
Conclusions: Metastatic pituitary carcinoma associated with acromegaly is particularly rare. To the best of our
knowledge, this is the eighth such case and is the first report of growth hormone and prolactin present in the
metastatic mass.
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Magnetic resonance imaging scans show that about 10%
of the healthy adult population have pituitary abnormal-
ities, which are likely asymptomatic pituitary adenomas
[1]. Most pituitary tumors are benign adenomas, and
adenocarcinomas are rare. A case report and review in
2011 [2] showed that 132 cases of pituitary carcinoma
had been recorded in 50 years. Growth hormone (GH)
was elevated in only seven cases, and prolactin was also
raised in one of these [3-9]. Acromegaly was the clinical
picture in three [3,8,9]. Visual impairment [4], headache
[5], and amenorrhea [7] were the chief symptoms in
another three, and no symptom details are available in
one case [6]. We report a further case of acromegaly with
metastatic pituitary carcinoma.* Correspondence: billtormey@gmail.com
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A 42-year-old Caucasian man complained of headache,
vomiting, and blurred vision. A pituitary tumor was diag-
nosed after a skull X-ray, and he received 3300 rad to
his sella. Two years later, he presented with impotence,
joint pains, and perspiration. His serum GH level was
16.2μg/L (reference range is 0.45 to 2.2) and was not sup-
pressed by the administration of oral glucose. His serum
testosterone level was subnormal at 423nmol/L (reference
range is 797 to 3470). His visual fields were normal, but
a skull X-ray demonstrated an enlarged sella. Acromegaly
with partial hypopituitarism was diagnosed. Further
radiation therapy (4000 rad) was administered, and he
received testosterone replacement. His GH levels were
normalized, but 3 years later hypothyroidism and hypo-
adrenalism were diagnosed, and appropriate replacement
therapies were begun.
Fourteen years after the initial diagnosis, his GH levels
again became elevated (25μg/L). A computed tomographyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Photomicrograph of a section of the mass removed
from the patient’s neck. The numerous dense core granules (long
arrow) indicate that the mass originated from neuroendocrine tissue.
Two globular fibrous bodies are also present in the section (one
marked with the short arrow). The bodies are suggestive of a
growth hormone-producing tumor.
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received therapy with up to 5mg of bromocriptine twice
daily for 1 year and then the drug was discontinued
because of intolerable side effects (nausea, headache, and
diarrhea). Surgical exploration was deemed inappropriate
because of previous irradiation, especially in the absence
of radiologic evidence of a pituitary mass. After 18 years,
a computed tomography scan, which was performed
because of progressive enlargement of the hands, feet,
and nose and an elevation of the GH level (104.5μg/L),
revealed a sellar mass. Attempted transsphenoidal explo-
ration was abandoned as a result of failed intubation.
Therapy with octreotide by subcutaneous injection was
initiated. The dose was gradually increased to the max-
imum approved level of 500mg three times daily and was
administered by continuous subcutaneous infusion. GH
levels were reduced to 14.5μg/L but not normalized.
After four more years, octreotide was discontinued and
therapy with pergolide commenced. However, GH levels
continued to increase.
Twenty-seven years into the disease course, the patient
developed a soft, painless, 4cm mass below the angle of
his right mandible. Fine-needle aspiration was suspicious
for lymphoma, and an excisional biopsy was performed.
Histopathology revealed tumor cells with abundant
pink cytoplasm. Electron microscopy demonstrated cells
containing membrane-bound dense core granules indi-
cative of a neuroendocrine tumor. Some cells contained
globular fibrous bodies of intermediate filaments suggest-
ive of a GH-secreting tumor (Figure 1). Immunohisto-
chemical staining was positive for synaptophysin, GH,
and prolactin but negative for other anterior pituitary
hormones. A diagnosis of metastatic pituitary carcinoma
was made.
The GH level decreased from 363μg/L before surgery
to 101μg/L but on subsequent follow-up began to rise
again. One year later, a radionuclide scan with indium-
labeled octreotide showed continued uptake in the region
of the sella, neck, and spleen. The patient declined fur-
ther investigation or active treatment for acromegaly and
was treated symptomatically before he died, at the age
of 72, 30 years after initial presentation.
Discussion
Pituitary carcinomas may be non-functioning or
hormone-secreting. In the review series on 132 pituitary
carcinomas [2], 23.5% were non-functioning, 36.4%
secreted prolactin only, 29.5% secreted adrenocortico-
tropic hormone only, and 0.2% secreted gonadotropin-
releasing hormone; there were individual cases of
thyroid-stimulating hormone (TSH) and luteinizing hor-
mone (LH) secretion and single cases of prolactin and
LH secretion and prolactin and TSH secretion. In the
GH cases, there were six women and this report is thesecond man. The age at presentation in the GH cases
ranged from 19 to 48 years, and the median age was
42 years. The commonest metastatic site for these cases
was the lymph nodes (in 50% of cases). Spinal and intra-
cranial sites were also reported as sites of metastases.
The present case is unique in the extent of proven and
potential metastases. Treatment modalities include sur-
gery, radiotherapy, bromocriptine, somatostatin analogs,
and chemotherapy. The duration of follow-up in these
cases ranged from 48 to 192 months and in this case was
27 years. The clinical picture at the time of reporting was
that three were stable and three had a partial response
to treatment; no information is available in the remaining
case. No postmortem information is available in any of
these cases.
Treatment of malignant pituitary tumors includes sur-
gery to remove the primary and metastatic tumor aug-
mented by conventional and stereotactic radiotherapy.
The mode of radiation depends on the availability of
technology with Gamma Knife
W
, linear accelerator, and
proton beam used. The relative value of stereotactic
radiosurgery in malignant cases awaits investigation. The
role of treatments with dopamine agonists cabergoline
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reotide and octreotide is case-dependent, but follow-up
should continue for life. Drugs that block GH receptors,
such as pegvisomant, may relieve symptoms but do not
reduce the tumor size and should not be used in malig-
nant cases.
GH production by the cervical metastasis was not un-
equivocally demonstrated, but reduction in GH following
surgical removal of the neck mass suggests that the con-
tinued GH production was originating, at least in part,
from the extracranial metastasis. Prolactin levels were
not measured for many years prior to the removal of
the metastasis and were subsequently undetectable.
However, the positive immunostaining for prolactin
in addition to GH in an extracranial metastasis from a
GH-producing tumor is a unique feature of the case [7].
The etiology of pituitary carcinoma is poorly under-
stood. It has been suggested that radiation may induce
mutations in tumor cells, making them more likely to
metastasize. A number of cases of sarcomas arising many
years after cranial irradiation in tissues previously
exposed to radiation have been reported [10,11]. High-
dose radiation therapy, particularly if given (as in this
case) in divided doses, has been implicated in their
pathogenesis. Our patient’s total radiation dose over the
course of 3 years was 7300 rad. Similarly, all but one [9]
of the other patients with GH-secreting pituitary carcin-
oma had received cranial irradiation for their primary
tumors. Radiotherapy is standard therapy in acromegaly
and is regarded as relatively safe in current modes.
Stereotactic radiotherapy, when available, is standard
[12]. An overview of pituitary carcinoma found that a
Ki-67 level of above 10% suggests increased metastatic
potential in pituitary tumors. Ki-67 is found in all active
phases of the cell cycle but not in resting cells. The roles
of p53, retinoblastoma gene, nm23 protein, H-ras onco-
gene, galectin-3, Her-2/neu protooncogene, cyclooxygen-
ase-2, and activated epidermal growth factor receptor in
pituitary tumors are also summarized [13].Conclusions
Metastatic pituitary carcinoma associated with acromegaly
is rare. To the best of our knowledge, this is the eighth
case and the first report of GH and prolactin present in
the metastatic mass.Consent
Despite all reasonable attempts, written informed con-
sent for publication from the patient’s next of kin could
not be obtained. The case is important to public health,
and every effort has been made to protect the identity of
our patient. There is no reason to believe that our
patient’s next of kin would object to publication.Abbreviations
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